Cannabidiol as a therapeutic target: evidence of its neuroprotective and neuromodulatory function in Parkinson’s disease

Simple item page
dc.audiencegeneralPublices_MX
dc.contributor.authorPatricio, Felipe
dc.contributor.authorMorales Andrade, Alan Axel
dc.contributor.authorPatricio Martinez, Aleidy
dc.contributor.authorLimón, Ilhuicamina Daniel
dc.creatorPATRICIO MARTINEZ, ALEIDY; 350139
dc.date.accessioned2023-02-02T19:21:48Z
dc.date.available2023-02-02T19:21:48Z
dc.date.issued2020-12-15
dc.description.abstract"The phytocannabinoids of Cannabis sativa L. have, since ancient times, been proposed as a pharmacological alternative for treating various central nervous system (CNS) disorders. Interestingly, cannabinoid receptors (CBRs) are highly expressed in the basal ganglia (BG) circuit of both animals and humans. The BG are subcortical structures that regulate the initiation, execution, and orientation of movement. CBRs regulate dopaminergic transmission in the nigro-striatal pathway and, thus, the BG circuit also. The functioning of the BG is affected in pathologies related to movement disorders, especially those occurring in Parkinson’s disease (PD), which produces motor and non-motor symptoms that involving GABAergic, glutamatergic, and dopaminergic neural networks. To date, the most effective medication for PD is levodopa (l-DOPA); however, long-term levodopa treatment causes a type of long-term dyskinesias, l-DOPA-induced dyskinesias (LIDs). With neuromodulation offering a novel treatment strategy for PD patients, research has focused on the endocannabinoid system (ECS), as it participates in the physiological neuromodulation of the BG in order to control movement. CBRs have been shown to inhibit neurotransmitter release, while endocannabinoids (eCBs) play a key role in the synaptic regulation of the BG".es_MX
dc.identifierhttps://doi.org/10.3389/fphar.2020.595635
dc.identifier.urihttps://hdl.handle.net/20.500.12371/17318
dc.language.isoenges_MX
dc.rights.accesopenAccesses_MX
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0es_MX
dc.subject.otherCannabidiol (CBD)es_MX
dc.subject.otherNeuroprotectivees_MX
dc.subject.otherNeuromodulatoryes_MX
dc.subject.otherl-DOPA-induced dyskinesiaes_MX
dc.subject.otherParkinson’s diasesees_MX
dc.titleCannabidiol as a therapeutic target: evidence of its neuroprotective and neuromodulatory function in Parkinson’s diseasees_MX
dc.typeArtículoes_MX
dc.type.conacytarticle
Files
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Investigadoras BUAP